Donepezil overdose - trending levels and symptoms

Allan R. Mottram 1, Elise ter Haar 2

1. Section of Emergency Medicine, University of Wisconsin, Madison WI, United States. 2. Section of Emergency Medicine, University of Wisconsin, Madison WI, United States.

Correspondence: Allan R. Mottram. Address: Section of Emergency Medicine, University of Wisconsin, Madison WI, United States. Email: armottram@medicine.wisc.edu

Received: March 5, 2014 Accepted: April 2, 2014 Online Published: April 10, 2014

DOI: 10.5430/crim.v1n2p80 URL: http://dx.doi.org/10.5430/crim.v1n2p80

Abstract
Donepezil (Aricept) is a reversible acetylcholinesterase inhibitor used in the treatment of dementia and cognitive impairment. Side effects of the drug include nausea, vomiting, diarrhea, muscle cramps, dizziness, fatigue and anorexia. Cholinergic symptoms may occur with overdose and may be severe. We report a case of donepezil toxicity with significant bradycardia during which serial donepezil levels were measured, and are correlated with the patients’ symptoms.

Keywords
Donepezil, Cholinergic, Toxicity, Bradycardia

1 Introduction
Donepezil (Aricept) is a reversible acetylcholinesterase inhibitor used in the treatment of mild to moderate dementia, and has been used in the treatment of mild cognitive impairment although this practice is not well supported [1-4]. Therapeutic levels are attained with doses of 5-10 mg/day, and peak plasma concentrations are reached 3-4 hours after oral administration. Its half life of elimination is 70 hours. Side effects of the drug include nausea, vomiting, diarrhea, muscle cramps, dizziness, fatigue and anorexia. Symptomatic bradycardia, respiratory insufficiency, syncope and complete AV block have also been reported [5-9]. We report a case of donepezil toxicity during which serial donepezil levels were measured, and are correlated with the patients symptoms.

2 Case report
A 53 year old otherwise healthy male with a history of memory loss was placed on donepezil by his primary care physician six months prior to his emergency department visit. The emergency department visit was for an acute accidental ingestion of up to twenty 10mg donepezil tablets, a dose that is 20-40 times the usual dose of donepezil. The patient reported ingesting the pills due to mistaking the bottle for his multivitamins, however the reliability of this history was questionable. He presented to the emergency department via ambulance approximately thirty to sixty minutes after the ingestion. It was reported that he immediately “felt sick”, sleepy and vomited twice. He was confused, somnolent, diaphoretic and bradycardic with heart rate in mid 30’s to 50’s in emergency department. An electrocardiogram demonstrated sinus bradycardia. 1mg intravenous atropine was administered due to the patients confusion and hemodynamic instability. A chest xray was obtained and demonstrated mild pulmonary congestion. A basic metabolic
panel and complete blood count were noted to be within the normal reference ranges. He was admitted to the medical intensive care unit for monitoring and supportive care.

The patient’s vital signs and cholinergic symptoms (nausea, vomiting, diarrhea and skin parameters) were recorded every 2 hours for 16 hours and then every four hours for the rest of his hospitalization. The patient was somnolent, nauseous and feeling cold (room temperature 80 degrees F) for first 8 hours. Over the next 8-16 hours, the patient became more alert and conversant, however he did have an episode of recurrent nausea and diaphoresis at 16 hours which was associated with food intake.

![Figure 1. Trends of Donepezil and RBC Cholinesterase](image)

Serum levels of donepezil and red blood cell cholinesterase levels were drawn in the emergency department and trended during his hospital stay. The initial donepezil level was 100ng/ml and decreased over three days to 57ng/ml at 36 hours, and 37mg/ml at 60 hours. The patients heart rate at these time points was 30-50 bpm (initial), 57 bpm (36 hours), and 64 bpm (60 hours). This bradycardia was not associated with hypotension. The trend in decreasing donepezil levels paralleled improvement in the patients other symptoms, with the cholinergic symptoms resolving over first 16 hours. The patient was discharged on the third hospital day with a heart rate of 64 and feeling much better. It was recommended that he stop using donepezil upon discharge.

### 3 Discussion

Donepezil was used in this case for treatment of mild cognitive impairment, though it should be noted that there is a lack of evidence to support this practice. In patients with cognitive impairment associated with Alzheimer’s disease, however, there is associated loss of cholinergic neurons within the brain and this cholinesterase inhibitor is thought to improve the function of remaining cholinergic neurons. In the case of our patient, he had been prescribed the medication and had been compliant with it for 6 months prior to the ingestion, so it is likely that he had a therapeutic level prior to the accidental ingestion. The initial donepezil level was 100ng/ml, which is significantly higher than what has been reported previously in a case of donepezil toxicity, with the prior reported level being 54.6 ng/ml. In this case, the patients donepezil level decreased over the following three days to 37ng/ml, which correlated with an improvement, then resolution, of symptoms on hospital day three. The estimated half life for elimination was just under 42 hours. The RBC anticholinesterase level was within normal range during entire hospitalization, but increased from 40 to 43 U/g hemoglobin over the hospitalization.
Conclusion

We report a case of donepezil overdose with serial donepezil levels. Our case report differs from prior cases in that the reported levels are higher, and the elimination half life appears shorter [5]. While this does not per se make our report unique, this variability in case reports is important as it speaks to the unpredictable nature of pharmacokinetics when considering supratherapeutic levels of drugs. Further, while we aim to provide a quantitative measure of this toxicity, one should, in general, treat the patient and not the “drug level”.

This patient experienced cholinergic symptoms with nausea, vomiting, confusion, somnolence, diaphoresis, and bradycardia. These symptoms were most prominent at donepezil levels of 100ng/ml, and resolved gradually over three days. The patient was asymptomatic at a donepezil level of 37ng/ml. The patient's symptomatic bradycardia occurred promptly after his ingestion, and responded well to intravenous atropine; he never demonstrated hypotension. He was admitted to the intensive care unit but did not require any further intervention during the remainder of his hospitalization, and was discharged in good condition.

This case illustrates that the effects of a donepezil overdose can be immediate and decrease over time with the elimination of the drug. Further, this case report supports the use of standard interventions such as atropine and good supportive care with adequate observation for mild to moderate cholinergic symptoms from donepezil toxicity.

References